What is the difference between Reclovir and Valganciclovir? Comparison of efficacy, ingredients and indications

In terms of antiviral treatment, especially for cytomegalovirus (CMV) infection, Licole (ganciclovir capsules) and Valganciclovir (Valganciclovir) are commonly used nucleoside antiviral drugs in clinical practice. Although they belong to the same drug family, they have essential differences in their component structure, body metabolism, efficacy performance, scope of indications, and clinical application scenarios. Understanding the similarities and differences between the two will not only help patients make the right choice under the guidance of a doctor, but also help optimize antiviral treatment plans, reduce side effects and improve treatment compliance.

From the ingredients point of view, the main active ingredient of Licole is ganciclovir (Ganciclovir), while the active ingredient of Vancevi is valganciclovir. Although both can eventually be metabolized in the body to the anti-CMV active ganciclovir triphosphate form, valganciclovir is the L-valine ester prodrug of ganciclovir and is an enhanced oral bioavailability version of ganciclovir. The oral absorption rate of ganciclovir itself is very limited, usually less than 10%, so it is more suitable for intravenous administration. Valganciclovir can be rapidly absorbed in the intestine after oral administration, and is rapidly hydrolyzed into ganciclovir in the liver and intestinal epithelial cells. Its bioavailability can be as high as about 60%, making Valganciclovir as an oral preparation far superior to Licolla in terms of therapeutic effect and compliance.

Secondly, there are also differences between the two in terms of efficacy. Valganciclovir (valganciclovir) has higher oral absorption efficiency, so it can replace intravenous ganciclovir in maintenance treatment. It is especially suitable for patients who require long-term oral treatment, such as for the prevention of CMV infection after organ transplantation, or the long-term management of HIV combined with CMV retinitis. According to overseas clinical studies, such as the IMPACT trial, valganciclovir is superior to oral ganciclovir in preventing CMV infection in kidney transplant recipients, and can significantly reduce the CMV infection rate and delay virological recurrence. In contrast, the oral formulation of Recole is less effective and is more regarded as an oral form of transitional therapy or a supplementary treatment to intravenous ganciclovir.

In terms of indications, Vancevi has been approved by multiple regulatory agencies around the world for two main uses: one is to treat CMV retinitis in HIV-infected patients; the other is to prevent CMV infection in solid organ transplant recipients. In addition to CMV-related indications, ganciclovir is also used to prevent viral infections after hematopoietic stem cell transplantation and refractory cases of HSV or VZV. However, due to its poor oral bioavailability, it is more commonly used in the acute infection stage in the form of injection. In comparison, valganciclovir has wider indication coverage, more convenient administration, and is more suitable for chronic CMV management and outpatient maintenance treatment.

From the perspective of adverse reactions, the two have similar toxicity profiles. The most common adverse reactions include neutropenia, anemia, thrombocytopenia, renal damage and gastrointestinal reactions, especially bone marrow suppression that requires close monitoring. Due to the high blood concentration of valganciclovir after oral absorption, some patients may experience more significant side effects in the early stages of treatment. Therefore, regular blood routine and renal function monitoring are required, especially when other immunosuppressants (such as cyclosporine and tacrolimus) are used in combination, the dose must be adjusted carefully.

Reference materials:https://go.drugbank.com/drugs/DB01610